Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Menu

    Olverembatinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma Presents Preclinical Studies at 2025 AACR Meeting
    Ascentage Pharma Presents Preclinical Studies at 2025 AACR Meeting

    28 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/28/3069043/0/en/Ascentage-Pharma-Presents-Results-from-Five-Preclinical-Studies-at-2025-American-Association-of-Cancer-Research-AACR-Annual-Meeting-Highlighting-Strong-Synergistic-Effects-of-Olver.html

    GLOBENEWSWIRE
    28 Apr 2025
    Share Share
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/21/3064563/0/en/Ascentage-Pharma-Announces-Inclusion-of-Lisaftoclax-and-Olverembatinib-in-Chinese-Society-of-Clinical-Oncology-CSCO-2025-Guidelines.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share
    Ascentage Pharma Reports Full Year 2024 Financial Results
    Ascentage Pharma Reports Full Year 2024 Financial Results

    27 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/27/3050422/0/en/Ascentage-Pharma-Reports-Full-Year-2024-Unaudited-Financial-Results-and-Business-Updates.html

    GLOBENEWSWIRE
    27 Mar 2025
    Share Share
    Olverembatinib Gets Breakthrough Status For Ph+ ALL Treatment
    Olverembatinib Gets Breakthrough Status For Ph+ ALL Treatment

    05 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/05/3037848/0/en/Olverembatinib-Granted-Breakthrough-Therapy-Designation-for-the-Treatment-of-Philadelphia-Chromosome-Positive-Ph-Acute-Lymphoblastic-Leukemia-ALL.html

    GLOBENEWSWIRE
    05 Mar 2025
    Share Share
    Olverembatinib Data Reaffirms Potential in Ponatinib Resistance
    Olverembatinib Data Reaffirms Potential in Ponatinib Resistance

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--1-5-year-follow-up-data-from-a-global-study-of-olverembatinib-reaffirms-potential-in-overcoming-resistanceintolerance-to-ponatinib-or-asciminib-302327550.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    1st Olverembatinib + Lisaftoclax Shows Potential for R/R Ph+ ALL
    1st Olverembatinib + Lisaftoclax Shows Potential for R/R Ph+ ALL

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--1st-dataset-of-olverembatinib-in-combination-with-bcl-2-inhibitor-lisaftoclax-demonstrates-potential-clinical-benefits-as-a-chemotherapy-free-regimen-for-children-with-rr-ph-all-302327474.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share